September #166 : When to START Drugs? - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Thou Shalt Fear AIDS

Lest We Forget

When to START Drugs?

You Said It

Burn that Belly

In Sync with ZInc

No Butts About It


HIV a Best Seller?

Considering Cannabis

The Importance of Remembering Ryan White

Insult to Injury

World Cup Wrap Up

Back-to-School Books

Angels Redux

Crying Uncle

Fear & Loathing in Illinois

Editor's Letter


Keeping Track

GMHC Treatment Issues- September 2010

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

Scroll down to comment on this story.

email print

September 2010

When to START Drugs?

by Tim Horn

A new study is designed to settle the debate about the optimal time to begin antiretroviral treatment.

When should positive people start taking HIV meds? It’s one of the most often asked questions among newly diagnosed people, yet it is one of the hardest to answer with certainty. “There are lots of opinions and ideas,” says Claire Rappoport, a research community liaison at the University of California at San Francisco (UCSF), “but there has never been a randomized clinical trial to [help] answer this question.”

The Strategic Timing of Antiretroviral Treatment (START) study hopes to settle the debate once and for all. The study will assess people who start antiretroviral meds before their CD4 cells drop below 500 (the current recommendation in the United States), rather than waiting until the CD4 count drops below 350 (the current recommendation in many other parts of the world). START is designed to determine whether beginning treatment at the higher CD4 level will extend disease-free survival without increasing the risk of adherence problems, drug resistance and side effects.

Before the end of 2010, the trial needs to recruit 900 people with CD4s above 500 who haven’t yet started HIV treatment, says Rappoport, who is a member of START’s community advisory board. If that recruitment goal is met, the researchers will then begin enrolling 4,000 participants for a definitive stage of the study. That phase will span two more years, plus an additional three years of follow-up.

Beyond purely altruistic motives, people might want to enroll in START for the possible personal benefits. “Paying for antiretroviral drugs can be an issue for many beginning treatment,” Rappoport says. “Most START sites [there are 70 throughout the world] will provide free antiretroviral treatment to participants. This may save on co-payments and other out-of-pocket expenses.”

Search for “START” at to learn more.   

Search: newly diagnosed. Strategic Timing of Antiretroviral Treatment, START, clinical trial

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.